18F-FSPG PET/CT for Cancer Patients on Therapy

Status Completed

Clinical Trial Summary

The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

Clinical Trial Description

OUTLINE:

Patients are evaluated with a PET/CT scan using the radiolabel 18F-FSPG [18F-(S)-4-(3-fluoropropyl)-L-glutamic acid] or 18F-FDG ([18F]-fluorodeoxyglucose), before and after therapeutic treatment.

PRIMARY OBJECTIVE:

Uptake of the radiolabel 18F-FSPG in patients with biopsy-proven cancer will be evaluated and compared to the uptake of 18F-FDG, before and after therapy (non-specified) in the same group of patients.

SECONDARY OBJECTIVES:

- Compare the agreement of the clinical assessment for cancer status between 18F-FSPG and 18F-FDG.

- Safety and tolerability of 18F-FSPG and 18F-FDG. ;

Study Design

Related Conditions & MeSH terms

B-Cell Neoplasm
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Estrogen Receptor Negative
HER2/Neu Negative
Lung Neoplasms
Lymphoma, B-Cell
Mesothelioma
Metastatic Renal Cell Cancer
Progesterone Receptor Negative
Stage III Mesothelioma
Stage III Renal Cell Cancer
Stage IIIA Breast Cancer
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Stage IV Mesothelioma
Stage IV Non-Small Cell Lung Cancer
Stage IV Renal Cell Cancer
Triple Negative Breast Neoplasms
Triple-Negative Breast Carcinoma

Clinical Trial Details

NCT number	NCT02599194
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Phase 2
Start date	July 2015
Completion date	December 14, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01987726` - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Terminated	`NCT01705340` - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	Phase 1
Terminated	`NCT01222377` - Endoscopic Breast Surgery in Treating Patients With Breast Cancer	N/A
Completed	`NCT00602043` - F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer	Phase 2
Completed	`NCT00425672` - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment	Phase 1/Phase 2
Completed	`NCT00244881` - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)	Phase 2
Completed	`NCT00096109` - Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer	Phase 2
Completed	`NCT00100750` - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT00096434` - Sorafenib in Treating Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT00057941` - Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer	Phase 2
Terminated	`NCT02892734` - Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer	Phase 2
Recruiting	`NCT03213041` - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer	Phase 2
Completed	`NCT02015559` - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus	Phase 2
Completed	`NCT02728596` - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)	N/A
Completed	`NCT03364348` - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer	Phase 1
Completed	`NCT02897375` - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors	Phase 1
Completed	`NCT01672684` - Phase I: At-Home Support for Rural Women Using Group Video Calling	Phase 1
Terminated	`NCT01233505` - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	Phase 1